A retrospective study of ipilimumab plus nivolumab in anti-PD-L1/PD-1-refractory merkel cell carcinoma.

被引：0
|
作者：
Shalhout, Sophia Z.
Emerick, Kevin S.
Kaufman, Howard E.
Miller, David M.
机构：
[1] Harvard Med Sch, Massachusetts Gen Hosp, Div Hematol Oncol, Dept Med, Boston, MA USA
[2] Harvard Med Sch, Dept Otolaryngol, Massachusetts Eye & Ear Infirm, Boston, MA USA
[3] Massachusetts Gen Hosp, Dept Surg, Boston, MA USA
[4] Massachusetts Gen Hosp, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9521
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Evaluation of niraparib in combination with anti-PD1/anti-PD-L1 in preclinical models
    Wang, Sarah
    Sun, Kaiming
    Xiao, Yonghong
    Feng, Bin
    Mikule, Keith
    Ramaswamy, Sridhar
    Hanke, Jeffrey
    Wang, Jing
    CANCER RESEARCH, 2018, 78 (13)
  • [42] New insights into the anti-PD-L1 and anti-PD-1 reagents in cancer therapy
    Chen, Cheng
    Huang, Jian-An
    EUROPEAN JOURNAL OF INFLAMMATION, 2016, 14 (01) : 61 - 65
  • [43] Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm
    Banna, Giuseppe Luigi
    Cantale, Ornella
    Bersanelli, Melissa
    Del Re, Marzia
    Friedlaender, Alex
    Cortellini, Alessio
    Addeo, Alfredo
    ONCOLOGY REVIEWS, 2020, 14 (02) : 135 - 143
  • [44] Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma
    Li, Mengqian
    LANCET ONCOLOGY, 2021, 22 (08): : E342 - E342
  • [45] The Curative Effect of Cryptotanshinone and anti-PD-L1 on Mouse Hepatocellular Carcinoma
    Han, Zhen
    Liu, Shuo
    Lin, Hongsheng
    Trivett, Anna
    Yang, De
    Oppenheim, Joost J.
    JOURNAL OF IMMUNOLOGY, 2018, 200 (01):
  • [46] Pre-treated anti-PD-1 refractory Merkel cell carcinoma successfully treated with the combination of PD-1/PD-L1 axis inhibitors and TVEC: a report of two cases
    Knackstedt, R.
    Sussman, T. A.
    McCahon, L.
    Song, J. -M.
    Funchain, P.
    Gastman, B.
    ANNALS OF ONCOLOGY, 2019, 30 (08) : 1399 - 1400
  • [47] Anti-PD(L)1 inhibition in patients with advanced Merkel cell carcinoma - real-world results of a retrospective, unicentre study
    Zaremba, A.
    Chorti, E.
    Reinboldt-Jockenhoefer, F.
    Lodde, G.
    Livingstone, E.
    Schadendorf, D.
    Becker, J. C.
    Ugurel, S.
    Zimmer, L.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2022, 20 : 114 - 114
  • [48] The PD-L1 Expression predicts the Outcome of anti-PD-1/PD-L1-based Immune Checkpoint Therapy in Patients with metastatic Merkel Cell Carcinoma
    Schielke, L.
    Hadaschik, E.
    Lodde, G. C.
    Albrecht, L. J.
    Sucker, A.
    Tasdogan, A.
    Roesch, A.
    Zimmer, L.
    Livingstone, E.
    Becker, J. C.
    Schadendorf, D.
    Ugurel, S.
    Placke, J. M.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2024, 22 : 17 - 18
  • [49] Anti-PD-L1 DNA aptamer antagonizes the interaction of PD-1/PD-L1 with antitumor effect
    Gao, Tian
    Mao, Zheng
    Li, Wenjing
    Pei, Renjun
    JOURNAL OF MATERIALS CHEMISTRY B, 2021, 9 (03) : 746 - 756
  • [50] Nivolumab plus ipilimumab with chemotherapy in metastatic NSCLC: minireview and a case study of a patient negative for PD-L1
    Morabito, Alessandro
    DRUGS IN CONTEXT, 2024, 13
12345